Braftovi (Encorafenib)
encorafenib 75 mg capsule, 42 · ORAL · PBS code 12814K
STREAMLINEDWhat it costs
AU$1675.18 PBS-determined price per 126 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-01-01.
- • Repeats: 3.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Metastatic colorectal cancer
Initial treatment
Patient must have BRAF V600 variant positive metastatic colorectal cancer; AND
The treatment must be in combination with cetuximab; AND
Patient must not have received prior treatment with cetuximab for this condition; or
Patient must not have developed disease progression while receiving cetuximab for this condition; AND
Patient must not have previously received PBS-subsidised treatment with this drug for this condition; AND
The condition must have failed to respond to at least one other line of systemic therapy; AND
Patient must have a WHO performance status of 2 or less.
Sponsor: Pierre Fabre Australia Pty Ltd ABN 30 098 999 850
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.